Daratumumab-Quadruplet Improves PFS in Transplant-Ineligible Myeloma
CEPHEUS subgroup data show daratumumab-VRd deepened MRD negativity and prolonged PFS in transplant-ineligible newly diagnosed multiple myeloma.
This section contains the website’s posts.